Business
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
REDWOOD CITY, Calif., August 01, 2025--Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients
About this update from Exicure, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2431,"height":600,"url":"https://media.zenfs.com/en/business-wire.com/0749c538b6458e9350014cb5fc88492a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/eud9VC6D_IegH._lTZLmVQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIzNztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0749c538b6458e9350014cb5fc88492a","width":960,"height":237},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/FNJ_YARLHeqM8yP4vksT8w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01OTI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/0749c538b6458e9350014cb5fc88492a","width":1200,"height":296}},"lazy":false},{"type":"text","content":"Topline results expected H2 2025","length":32,"tagName":"p","attribs":{}},{"type":"text","content":"REDWOOD CITY, Calif., August 01, 2025--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last patient, last visit in its ongoing Phase 2 clinical trial (NCT05561751) evaluating the safety and efficacy of GPC-100 (burixafor) in combination with propranolol and G-CSF in multiple myeloma patients undergoing autologous stem cell transplant (ASCT). Topline results from the study are expected in the fourth quarter of 2025.","length":543,"tagName":"p"},{"type":"text","content":"The randomized, open-label, multicenter study is designed to assess whether GPC-100, a small molecule CXCR4 antagonist, can improve CD34+ hematopoietic stem cell mobilization from the bone marrow into the peripheral blood, where they can be collected via leukapheresis for use in ASCT. In data presented at ASH 2024, GPC-100 appears to be well differentiated in terms of the speed with which it mobilizes stem cells compared to currently approved stem cell mobilization treatments.","length":481,"tagName":"p"},{"type":"text","content":"Dr. Muthalagu Ramanathan, Director of the Myeloma Program and Medical Co-Director of the Blood and Marrow Transplant and CAR-T Program at U Mass Memorial Health noted that "traditionally, patients undergoing mobilization are required to come, as an outpatient, the night before their procedure to receive the mobilization injection — a process that adds logistical challenges. The stud...